Raseglurant

Raseglurant

Systematic (IUPAC) name
2-[(3-Fluorophenyl)ethynyl]-4,6-dimethyl-3-pyridinamine
Identifiers
CAS Number	757950-09-7
ATC code	None
PubChem	CID 10331863
ChemSpider	8507323
Chemical data
Formula	C15H13FN2
Molar mass	240.276 g/mol
SMILES Fc2cccc(C#Cc1nc(cc(c1N)C)C)c2
InChI InChI=1S/C15H13FN2/c1-10-8-11(2)18-14(15(10)17)7-6-12-4-3-5-13(16)9-12/h3-5,8-9H,17H2,1-2H3 Key:MEDCLNYIYBERKO-UHFFFAOYSA-N

Raseglurant (INN) (code name ADX-10059) is a negative allosteric modulator of the mGlu₅ receptor and derivative of MPEP which was under development by Addex Therapeutics for the treatment of migraine, gastroesophageal reflux disease, and dental anxiety.^[1][2] It reached phase II clinical trials for all of the aforementioned indications before being discontinued due to the observation of possible predictive signs of hepatotoxicity in patients with long-term use.^[2][3][4]

See also

• Basimglurant
• Dipraglurant
• Fenobam
• Mavoglurant

References

1. Annual Reports in Medicinal Chemistry. Academic Press. 31 December 2012. pp. 80–. ISBN 978-0-12-397214-9.
2. Murray B. Stein; Thomas Steckler (30 July 2010). Behavioral Neurobiology of Anxiety and Its Treatment. Springer Science & Business Media. pp. 397–. ISBN 978-3-642-02912-7.
3. Celia Dominguez (18 November 2010). Neurodegenerative Diseases. Springer Science & Business Media. pp. 120–. ISBN 978-3-642-16758-4.
4. Nicholas J. Shaheen (25 March 2013). Benign and Neoplastic Conditions of the Esophagus, An Issue of Gastroenterology Clinics,. Elsevier Health Sciences. pp. 119–. ISBN 1-4557-7175-9.

External links

• Development of ADX10059 Ended for Long-term Use - Addex Therapeutics